Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines

Molecular Medicine

Jianhua Li¹  Ping Wang²  Haichao Wang²  Kevin J. Tracey² 

[1] The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, 11030, Manhasset, NY, USA;The Feinstein Institutes for Medical Research, Northwell Health, 350 Community Drive, 11030, Manhasset, NY, USA;Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 500 Hofstra Blvd, 11549, Hempstead, NY, USA;

关键词: GM-CSF;    SARS-CoV-2;    Spike protein;    Antibody;   

DOI  :  10.1186/s10020-021-00313-3

来源: Springer

【 摘 要 】

A SARS-like coronavirus 2 (SARS-CoV-2) has caused a pandemic Coronavirus Disease 2019 (COVID-19) that killed more than 3.3 million people worldwide. Like the SARS-CoV, SARS-CoV-2 also employs a receptor-binding motif (RBM) of its spike protein to bind a host receptor, the angiotensin-converting enzyme 2 (ACE2), to gain entry. Currently, several mRNA or adenoviral vaccines encoding for the spike protein of SARS-CoV-2 are being used to boost antibodies capable of inhibiting spike-ACE2 interaction and viral entry. However, recent evidence has also suggested an anti-inflammatory effect of spike-reactive antibodies, suggesting that some SARS-CoV-2 spike-based vaccines may elicit protective antibodies capable of inhibiting GM-CSF production and COVID-19 progression.

【 授权许可】

CC BY